GALT
Income statement / Annual
Last year (2025), Galectin Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Galectin Therapeutics Inc's net income was -$30.84 M.
See Galectin Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$37.00 K
|
$33.00 K
|
$32.00 K
|
$41.00 K
|
$36.00 K
|
$35.00 K
|
$0.00
|
$1.00 K
|
$7.00 K
|
| Gross Profit |
$0.00
|
-$37.00 K
|
-$33.00 K
|
-$32.00 K
|
-$41.00 K
|
-$36.00 K
|
-$35.00 K
|
$0.00
|
-$1.00 K
|
-$7.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$14.29 M
|
$36.57 M
|
$32.13 M
|
$31.74 M
|
$23.82 M
|
$17.98 M
|
$7.47 M
|
$6.47 M
|
$11.72 M
|
$15.33 M
|
| General & Administrative Expenses |
$5.80 M
|
$0.00
|
$5.90 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.13 M
|
$4.53 M
|
$6.16 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$44.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.80 M
|
$5.83 M
|
$5.94 M
|
$6.58 M
|
$6.32 M
|
$5.43 M
|
$5.94 M
|
$7.13 M
|
$4.53 M
|
$6.16 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$20.09 M
|
$42.40 M
|
$38.04 M
|
$38.32 M
|
$30.14 M
|
$23.41 M
|
$13.40 M
|
$13.60 M
|
$16.25 M
|
$21.48 M
|
| Cost And Expenses |
$20.09 M
|
$42.43 M
|
$38.07 M
|
$38.35 M
|
$30.18 M
|
$23.44 M
|
$13.44 M
|
$13.60 M
|
$16.25 M
|
$21.48 M
|
| Interest Income |
$126.00 K
|
$338.00 K
|
$230.00 K
|
$52.00 K
|
$3.00 K
|
$66.00 K
|
$231.00 K
|
$38.00 K
|
$24.00 K
|
$45.00 K
|
| Interest Expense |
$7.33 M
|
$5.54 M
|
$2.79 M
|
$1.03 M
|
$489.00 K
|
$87.00 K
|
$87.00 K
|
$336.00 K
|
$12.00 K
|
$0.00
|
| Depreciation & Amortization |
$53.00 K
|
$37.00 K
|
$33.00 K
|
$32.00 K
|
$41.00 K
|
$36.00 K
|
$35.00 K
|
$1.00 K
|
$1.00 K
|
$7.00 K
|
| EBITDA |
-$23.45 M |
-$41.47 M |
-$38.24 M |
-$37.71 M |
-$30.00 M |
-$23.34 M |
-$13.17 M |
-$13.56 M |
-$16.23 M |
-$21.47 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$10.75 M
|
-$4.61 M
|
-$2.99 M
|
-$424.00 K
|
-$348.00 K
|
-$21.00 K
|
$144.00 K
|
-$298.00 K
|
$12.00 K
|
$45.00 K
|
| Income Before Tax |
-$30.84 M
|
-$47.05 M
|
-$41.07 M
|
-$38.78 M
|
-$30.53 M
|
-$23.47 M
|
-$13.29 M
|
-$13.90 M
|
-$16.24 M
|
-$21.44 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$30.84 M
|
-$47.05 M
|
-$41.07 M
|
-$38.78 M
|
-$30.53 M
|
-$23.47 M
|
-$13.29 M
|
-$13.90 M
|
-$16.24 M
|
-$21.44 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.48 |
-0.76 |
-0.74 |
-0.65 |
-0.52 |
-0.41 |
-0.39 |
-0.35 |
-0.46 |
-0.73 |
| EPS Diluted |
-0.48 |
-0.76 |
-0.74 |
-0.65 |
-0.52 |
-0.41 |
-0.39 |
-0.35 |
-0.46 |
-0.73 |
| Weighted Average Shares Out |
$63.90 M
|
$62.31 M
|
$60.16 M
|
$59.39 M
|
$58.53 M
|
$57.03 M
|
$52.24 M
|
$39.41 M
|
$35.52 M
|
$29.22 M
|
| Weighted Average Shares Out Diluted |
$63.90 M
|
$62.31 M
|
$60.16 M
|
$59.39 M
|
$58.53 M
|
$57.03 M
|
$52.24 M
|
$39.41 M
|
$35.52 M
|
$29.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
